Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US ...

Haleon launched a share buyback programme of up to £330m on Friday, representing the remaining portion of the £500m allocated ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Cocoa extract supplementation among older adults had no effect overall on the occurrence of age-related macular degeneration ...

Global IPO markets made steady gains in 2024, with IPO proceeds increasing compared to the previous year as the high interest ...

This year’s unexpected demand for European stocks is helping to drive the region’s largest wave of block sales this century, ...

A federal judge in Florida has acknowledged that she created the appearance of bias when she stated that women needed to be adequately represented among the lawyers who would be assigned to serve ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Kotak Alternate Asset Managers have announced an investment of ₹1,050 crore in Tirupati Medicare Ltd, a contract development ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).